1. This study developed a detection method based on the strategy of HPLC/MS3 to quantify carbamazepine in human plasma.
2. The LC-MS3 method was validated for accuracy, precision, selectivity, linearity, and LLOQ.
3. The LC-MS3 method was successfully used to monitor the blood concentration of epilepsy patients after carbamazepine treatment.
The article is generally reliable and trustworthy as it provides detailed information about the development and validation of an LC-MS3 method for quantifying carbamazepine in human plasma. The authors provide evidence for their claims by citing relevant studies and providing data from experiments conducted during the development of the method. Furthermore, they discuss potential risks associated with using this method and provide recommendations for further research.
However, there are some areas where the article could be improved upon. For example, while the authors discuss potential risks associated with using this method, they do not provide any evidence or data to support these claims. Additionally, while they cite relevant studies throughout the article, they do not explore any counterarguments or present both sides equally when discussing potential risks associated with using this method. Finally, there is a lack of discussion regarding possible biases in the data collected during experiments conducted during the development of this method which could lead to inaccurate results if not addressed properly.